AUG 14, 2026 · JOURNAL ARTICLE
A Preliminary Evaluation of 177Lu-PSMA-617-Based Targeted Radioligand Therapy with X-Ray Stimulated PSMA Relocation Using the PiggyBac Reporter-Gene-Engineered Orthotopic Prostate Tumor Model
Pharmaceutics
Early-phase preclinical study in engineered xenograft models evaluating a novel combination approach; no clinical efficacy data, surrogate endpoints only, and single-arm treatment groups without formal statistical comparison.
Reported
Bioluminescence detection timefra…within one week
Bioluminescence persistenceat least five weeks
X-ray dose2 Gy